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Foxp3+CD25+CD4+ regulatory T cells are vital for peripheral tolerance and control of tissue inﬂammation. In this study, we
characterized the phenotype and monitored the migration and activity of regulatory T cells present in the airways of allergic or
tolerant mice after allergen challenge. To induce lung allergic inﬂammation, mice were sensitized twice with ovalbumin/aluminum
hydroxide gel and challenged twice with intranasal ovalbumin. Tolerance was induced by oral administration of ovalbumin for 5
consecutive days prior to OVA sensitization and challenge. We detected regulatory T cells (Foxp3+CD25+CD4+ Tc e l l s )i nt h e
airways of allergic and tolerant mice; however, the number of regulatory T cells was more than 40-fold higher in allergic mice than
in tolerant mice. Lung regulatory T cells expressed an eﬀector/memory phenotype (CCR4highCD62LlowCD44highCD54highCD69+)
that distinguished them from naive regulatory T cells (CCR4intCD62LhighCD44intCD54intCD69−). These regulatory T cells
eﬃciently suppressed pulmonary T-cell proliferation but not Th2 cytokine production.
1.Introduction
Regulatory T (Treg) cells have been implicated in the mech-
anisms that govern peripheral dominant tolerance. From
autoimmunity, transplantation, and cancer to mucosal tol-
erance, the presence of functional Treg cells, either thymus-
derivednaturallyoccurringorperipherally-inducedadaptive
Treg cells have been associated with the control of inﬂamma-
tion [1].
Allergic asthma is a chronic inﬂammatory disease char-
acterized by airway eosinophilia, airway hyperreactivity
(AHR), mucous hypersecretion, and high titers of IgE [2].
In asthmatic patients, CD4+ Tl y m p h o c y t e su p o na l l e r g e n
challenge secrete type-2 cytokines such as IL-4, IL-5, IL-9,
andIL-13thatinturnmediatetheTh2-associatedinﬂamma-
tory network and IgE production [3]. It has been suggested
that insuﬃcient immune regulation by Treg cells might
lead to aberrant Th2 response [4–7]. Conversely, mucosal
exposure to nonpathogenic antigens results in a state
of hyporesponsiveness, known as mucosal tolerance that
eﬃciently inhibit pulmonary and systemic Th2-mediated
response [8–12].
Diﬀerent subtypes of regulatory T cells or suppressive
cytokines have increasingly been deﬁned as important in
mediating T-cell unresponsiveness by mucosal tolerance
[9, 13–15]. For instance, TGF-β-producing Th3 cells and2 Clinical and Developmental Immunology
IL-10-producing Tr1 cells were proposed to mediate oral
and nasal tolerances, respectively [9, 16, 17]. Other Treg
cells involved in mucosal tolerance have been character-
ized as CD4+CD25+CD45RBlow T cells that also express
glucocorticoid-induced TNF receptor (GITR), CTLA-4, and
Foxp3 [13, 14, 18–23].
T h ei n v o l v e m e n to fT r e gc e l l si nt h ec o n t r o lo fa l l e r g i c
responses was clearly established in double T/B transgenic
mice [7], a mice that harbor monoclonal CD4+ T-cell
population speciﬁc to OVA and monoclonal B cells speciﬁc
to hemagglutinin A (HA). These animals when devoid of
natural Treg cells develop hyper-IgE response upon OVA-
HA sensitization and challenge [7]. Previously, we have
shown that oral tolerance induced by OVA feeding prevented
the development of hyper-IgE production and asthma-like
responses in these animals [24]. We found that oral OVA
exposure induced the development of adaptive OVA-speciﬁc
Treg cells that displayed suppressive activity in vivo and
in vitro in a TGFβ-dependent manner [24] indicating that
Tregs are quite eﬃcient in preventing priming of naive
T cells.
Natural or adaptive Treg cells can be further charac-
terized as naive or eﬀector Treg cells by the expression of
chemokine receptors and adhesion molecules responsible for
their preferential localization in lymph nodes or in inﬂamed
tissues [25]. The suppressive eﬀect of Treg cells in lymph
nodes is well documented, whereas their role at sites of
allergen challenge is still elusive. It has been reported that
theresolutionofallergicairwaydiseaseinducedbylong-term
allergen challenge (inhalational tolerance) is associated with
local accumulation of Treg cells [26]. Previous studies that
employed oral or nasal tolerance to suppress OVA-induced
allergic lung disease did not investigate the migration of Treg
cells to the lung [23, 24].
In the present work, using the murine OVA model of
asthma-like responses, we investigated whether Treg cells
migrate to the site of allergen challenge in allergic mice or
in mice made tolerant by OVA feeding before sensitization
(oral tolerance). Because we found that Foxp3+ Treg cells
as well as Th2 inﬂammatory cells and high levels of
suppressive cytokines accumulated in the airways of allergic
but not in tolerant mice, we further characterized the
phenotype of these Treg cells. Upon allergen challenge,
Treg cells accumulated into airways of allergic mice and
showed upregulation of the chemokine receptor CCR4 and
substantially downregulation L-selectin. These two surface
markers could, at least, distinguish Treg cells present in
the airways (CCR4highCD62Llow) from those present in the
draining lymph nodes (CCR4intCD62Lhigh). In addition,
airway Treg cells also upregulated molecules associated with
eﬀe c t o r / m e m o r yTc e l l ss u c ha sC D 5 4 ,C D 4 4 ,a n do t h e r s
[27, 28]. Interestingly, the increased frequency of Foxp3+
Treg cells in the allergic lung expressed CD69, whereas
the majority of lung Treg cells from tolerant mice were
Foxp3+CD69-negative. Finally, airway CD4+CD25+ Treg-
like cells from allergic mice exhibited strong and eﬃcient
antiproliferative activity on lung CD4+CD25− T cells but
were unable to suppress type 2 cytokine production. Indeed,
experiments with highly puriﬁed green ﬂuorescent Foxp3
Treg cells conﬁrmed the inability of these cells to suppress
cytokine production by Th2 cells.
2.MaterialsandMethods
2.1. Mice. Female BALB/c and C57BL/6 mice at 8–12-week
old, housed under speciﬁc pathogen-free conditions at the
Department of Immunology, Biomedical Science Institute,
University of S˜ ao Paulo, Brazil, were used throughout
the experiments. Foxp3-green ﬂuorescence protein knockin
(Foxp3gfp.KI) mice were already described elsewhere [29];
these animals were kindly provided by Howard L. Weiner
(Center for Neurologic Diseases, Brigham and Women’s
Hospital, Harvard Medical School) and were bred at the
Department of Microbiology, Immunology and Parasitology
of Federal University of S˜ ao Paulo. Mice were treated
according to Animal Welfare guidelines of the Biomedical
Science Institute (ICB-USP).
2.2. OVA Sensitization and Airway Challenge. Mice were
sensitized and boosted by subcutaneous route with 4μg
chicken OVA/1.6mg of aluminum hydroxide gel in 0.2mL
of sterile PBS at days 0 and 7. For the induction of airway
inﬂammation, mice receive two intranasal (i.n.) challenges
with 10μgO V Ai n4 0μL of sterile PBS at days 14 and 21.
Experiments were performed 24h after the last i.n. OVA
challenge (day 22).
2.3. Oral Tolerance Induction. Oral tolerance to OVA was
induced by spontaneous intake of 1% OVA (grade V, Sigma-
Aldrich, St. Louis, Mo USA) solution dissolved in sterile
drinking water for 5 consecutive days before sensitization as
previously described [24].
2.4. Bronchoalveolar Lavage (BAL). Mice were deeply anes-
thetized, trachea was cannulated, and lungs were rinsed with
1.0mL of cold PBS. Total and diﬀerential cell counts of
BAL ﬂuid were determined by hemocytometer and cytospin
preparation stained with Instant-Prov (Newprov, Brazil).
2.5. Determination of Respiratory Pattern. Respiratory pat-
tern was determined before and after increasing doses of
inhaled methacholine (3, 6, 12, and 25mg/mL) in con-
scious unrestrained mice using whole-body plethysmograph
(Buxco Electronics Inc. Wilmington, NC, USA) as previ-
ously described [12, 30]. The enhanced pause (Penh), a
dimensionless value that takes into account box pressure
recorded during inspiration and expiration and the timing
comparison of early and late expiration was used to deﬁne
the respiratory pattern.
2.6. Flow Cytometry Analysis. Single cell suspensions were
preincubated with FcBlock for 10 min at room temperature
(BD PharMingen, San Diego, Calif, USA). Cells were then
incubated in staining buﬀer (PBS containing 2% fetal
calf serum and 0.1% NaN3)f o r3 0 m i na t4 ◦C with the
antibody cocktails. Samples were analyzed in FACSCalibur
or FACSCanto II instruments (Becton Dickinson, San Diego,Clinical and Developmental Immunology 3
Calif, USA). Anti-mouse CD4-FITC, CD4-PerCP, CD4-
Paciﬁc Blue, CD25-PerCP-Cy5.5, CD25-FITC, CD62L-PE,
CD69-FITC, CTLA-4-PE, GITR-PE, IgG2aκ-PE, IgG2aκ-
FITC, IL-10-PE, IL-5-PE, and streptavidin-PE-Cy5 were
purchased from BD Pharmingen (San Diego, Calif, USA).
Anti-mouse Foxp3-APC and Foxp3-FITC antibodies were
purchased from e-Biosciences (San Diego, Calif, USA).
Aﬃnity-puriﬁed biotinylated goat anti-TGF-β-bound pre-
cursor cytokine latency-associated peptide (LAP) polyclonal
antibodieswerepurchasedfromR&DSystems(Minneapolis,
Minn, USA). The remaining antibodies CCR4-APC, CD44-
PE, CD54-PE, and CCR7-PerCP-Cy5.5 were purchased from
BioLegend (San Diego, Calif, USA).
2.7. Intracellular Staining for Foxp3, CTLA-4, and Cytokines.
After stimulation with 2μg/mL anti-CD3 for 8h in the
presence of Monensin (Sigma-Aldrich) at 37◦C, cells were
ﬁrst surface stained and then permeabilized for 30min with
Cytoﬁx/Cytoperm kit (BD Pharmingen). After washing, cells
were stained with anti-IL-10 and IL-5 antibodies for 45min
at 4◦C. For Foxp3 and CTLA-4 intracellular staining, an
additional permeabilization was performed using a Foxp3
Staining Buﬀer Set (eBiosience) for 30min at 4◦C. Samples
were analyzed in a FACSCalibur or FACSCanto II instru-
ments (Becton Dickinson, San Diego, Calif, USA).
2.8. Lung Digestion and Cell Sorting. After bronchoalveolar
lavage, pieces of lung tissue were digested with collage-
nase (2mg/mL) and DNase (1mg/mL) (Sigma-Aldrich)
at 37◦C for 30min. Lung CD4+CD25− and CD4+CD25+
cells were isolated using magnetic cell sorting (Miltenyi
Biotec). First, CD4+ cells were negatively isolated using
MicroBeads to MHCII, CD8a, and B220 (Miltenyi Biotec).
Negative cells were then magnetically labeled to CD25 and
isolated CD4+CD25− (>95%) and CD4+CD25+ (>90%)
cells assessed by ﬂow cytometry. In selected experiments,
lung cells from allergic Foxp3gfp.KI mice were staining for
CD4-Paciﬁc Blue and sorted into CD4+Foxp3-GFP− and
CD4+Foxp3-GFP+ using a FACSAria cell sorter (Becton
Dickinson).
2.9. In Vitro Suppression Assay. The suppression assay was
performedwithCD4+CD25+ cellspuriﬁedbymagneticsort-
ing or with highly puriﬁed FACS-sorted CD4+ Foxp3-GFP+
obtained from Foxp3gfp.KI mice. For this, CD4+CD25− and
CD4+CD25+ cells were puriﬁed using magnetic sorting.
Proliferation assays were set up in 96-well round-bottom
plates and contained, per well, 2 × 104 responder cells
(CD4+CD25− cells from sensitized and challenged BALB/c
mice), 4 × 104 APCs (Mitomycin C-treated spleen cells
from TCRαβ-deﬁcient BALB/c mice or from nude mice),
and anti-CD3 (145-2C11) antibody at a 1μg/mL. Cells were
cocultured at CD25−/CD25+ ratios of 1:1, 1:0.3, and 1:0.1.
Proliferationwasdeterminedbyadding 3H-thymidineonthe
third day of culture and determining incorporation 6h later.
Suppression assay with CD4+ Foxp3-GFP+ was performed
with lung CD4+ Foxp3-GFP+ or Foxp3-GFP− T cells that
wereFACS-sortedfromallergicFoxp3gfp.KImice.Responder
cells (CD4+Foxp3-GFP−) were labeled with 5μMo fCell
Proliferation Dye eFluor-670 (eBiosciences, San Diego, Calif,
USA) according to the manufacturer’s recommendations.
Dye labeled CD4+Foxp3-GFP− Tc e l l s( 2× 105) were than
cultured without or with CD4+Foxp3-GFP+ Treg cells at
ratios of 1:1, 1:0.3, and 1:0.1 in the presence of 4 ×
105 APCs (spleen cells from RAG−/− mice) and anti-CD3
(1μg/mL) for 72h. The proliferation was determined by
reduction of the ﬂuorescence intensity of Dye eFluor-670
using a ﬂow cytometry instruments. For analysis of IL-4 and
IL-5production,respondercells(2×104 CD4+Foxp3-GFP−)
werecoculturedwithoutorwithCD4+Foxp3-GFP+ Treg cells
in the presence of 35 Gy-irradiated lung MHCII+ MACS-
puriﬁed cells (4 × 104)f r o mFoxp3gfp.KI mice and anti-
CD3 (1μg/mL). Cytokine concentrations were quantiﬁed
by sandwich kit ELISA according to the manufacturer’s
recommendations as previously described [8].
2.10. Determination of OVA-Speciﬁc IgE and IgG1 Anti-
bodies. OVA-speciﬁc antibodies were assayed by sandwich
ELISA as previously described [8]. For OVA-speciﬁc IgE
determinations, plates were coated overnight at 4◦Cw i t h
2μg/mLofgoatanti-mouseIgEantibody(SouthernBiotech-
nology). Serum samples were added followed by addition
of biotin-labeled OVA. Bound OVA-biotin was revealed
by Streptavidin Peroxidase conjugate (Sigma) as previ-
ously described [8]. Hyperimmune serum from OVA/Alum-
immunized BALB/c mice was used as IgE standard and
arbitrarily assigned as 10.000U/mL. For OVA-speciﬁc IgG1
antibodies,serumsampleswereplatedon96wellspreviously
coated with OVA (2μg/well). The bound antibodies were
revealed with goat anti-mouse IgG1 followed by peroxidase-
labelled rabbit anti-goat antibodies (all from Southern
Biotechnology).TheconcentrationofOVA-speciﬁcantibody
was estimated by comparison with IgG1 standards run in
parallel as previously described [8].
2.11. Cytokine Determinations. The levels of IL-4, IL-5, IL-
10, IL-13, and TGF-β in the BAL ﬂuid or supernatants
from lung cells culture were assessed by a sandwich kit
ELISA according to the manufacturer’s recommendations
as previously described [8]. Values are expressed as pg/mL
deduced from standards run in parallel with recombinant
cytokines. Puriﬁed and biotinylated antibodies to IL-4, IL-5,
and IL-10 kits were from BD OptEIA, San Diego, Calif, USA.
IL-13kitwasfromR&DSystemsandTGF-β1 from Promega,
Madison, Wis, USA.
2.12. Lung Histology. Lungs were perfused via the right
ventricle with 10mL of cold PBS, removed, and immersed in
10% phosphate-buﬀered formalin for 24h and then in 70%
ethanol until embedding in paraﬃn. Tissues were sliced and
5μm sections were stained with hematoxylin/periodic acid-
Schiﬀ (PAS) for analysis of cellular inﬂammation and mucus
production.
2.13. Statistical Analysis. ANOVA was used to determine the
levels of diﬀerence between all groups. Comparisons of all4 Clinical and Developmental Immunology
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Figure 1: Oral tolerance prevents airway allergic disease. (a) Respiratory pattern to increasing dose of methacholine (MCh) in control,
allergic, or tolerant BALB/c mice 24h after the last OVA challenge. (b) BAL diﬀerential cell counts. Quantiﬁcation by ELISA of (c) IL-5, (d)
IL-13 in the BAL ﬂuid, and (e) anti-OVA IgE, (f) IgG1 in the serum. (g) Histology of lung sections at 100x. Lung parenchyma inﬂammation
and mucus production by goblet cells are shown in representative lung sections stained with hematoxylin/PAS. Values represent the means ±
SEM for groups of ﬁve mice and are representative of more than three experiments. Signiﬁcant diﬀerences ∗P<0.05, ∗∗P<0.01, and
∗∗∗P<0.001 are shown.
pairs were performed by Tukey-Kramer honestly signiﬁcant
diﬀerence test. Values for all measurements are expressed as
mean ± SEMs, and the P values for signiﬁcance were set to
0.05.
3. Results
3.1. Oral Tolerance Prevents the Development of Asthma-Like
Responses. OVA-sensitized and -challenged mice (Allergic)
developed an enhanced ventilation as revealed by Penh
values to increasing doses of methacholine (MCh) com-
pared to untreated mice (Control). Conversely, prior oral
administration of OVA (Tolerant) prevented the increase in
ventilation (Figure 1(a)). Diﬀerential cell counts showed an
increased number of mononuclear cells, neutrophils, and
mainly eosinophils in allergic mice compared to control
mice. In tolerant mice, the inﬂux of inﬂammatory cells was
almost completely absent (Figure 1(b)). The levels of type-2
cytokines IL-5 and IL-13 in the BAL (Figures 1(c) and 1(d))
andtheserumlevelsofOVA-speciﬁcIgEandIgG1antibodiesClinical and Developmental Immunology 5
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Figure 2: Regulatory T cells in lymphoid organs. Frequency of Foxp3+CD4+ T cells in (a) spleen, (b) cervical lymph nodes (cLN), and
(c) mesenteric lymph nodes (mesLN) of C57BL/6 fed or not with OVA before and after OVA/Alum sensitization. Cells recovered from the
diﬀerent lymphoid organs were stained for CD4 and Foxp3 and gated in CD4-positive cells. Values are representative of two independent
experiments with pooled cells from three animals per group.
(Figures 1(e) and 1(f)) were also significantly increased in
allergic mice than those orally OVA exposed. Furthermore,
lung histology of allergic mice showed intense peribronchial
and perivascular inﬂammatory inﬁltrates and mucus hyper-
secretion, determined by PAS staining (Figure 1(g)). In
contrast, tolerant mice exhibited lung histology similar to
control group (Figure 1(g)). These data show and conﬁrm
[12] that OVA-feeding before sensitization eﬃciently sup-
presses airway allergic responses and systemic IgE antibody
production.
3.2. OVA-Feeding Increase Regulatory T Cells in Spleen after
Antigen Sensitization. We and others have previously shown
that adaptive CD4+CD25+ (Foxp3+) regulatory T (Treg)
cells increase in peripheral lymphoid organs after oral
OVA administration in mice with monoclonal OVA-T-cell
receptor repertoire [13, 14, 18–23]. Here we were interested
in determining whether oral OVA in mice with polyclonal T-
cell repertoire could also increase the frequency of Treg cells.
For this we monitored the frequency of CD4+Foxp3+ Treg
cells detected in spleen, mesenteric lymph nodes (mesLN),
and cervical-draining lymph nodes (cLN) before and after
OVA sensitization in mice that received previously OVA or
not in the drinking water. We found that the frequency of
CD4+Foxp3+ Treg cells increased at day 3 (d.3) after s.c.
OVA sensitization in the spleen of tolerant but not allergic
mice and decreased thereafter (Figure 2(a)). No diﬀerences
were observed between tolerant and allergic mice when the
percentages of CD4+Foxp3+ Treg cells were quantiﬁed in
cLN and mesLN (Figures 2(b) and 2(c), resp.). These results
show that oral OVA administration leads to an increased
frequency of spleen Treg cells even in mice with polyclonal
T-cell repertoire.
3.3. Regulatory T Cells Accumulate in the Airways of Allergic
but Not in Tolerant Mice. To monitor the appearance of Treg
cells in the airways the number of CD4+CD25+Foxp3+ cells
present in the BAL and in the lung tissue were determined
from days 14 to 22 (before and after OVA challenges) in mice
that received or not OVA in the drinking water. Interestingly,
we found an increased number of Foxp3+ Treg cells in the
BAL of allergic but not tolerant mice. An apparent increase
of these cells was found at day 17, that is, 48h after the ﬁrst
OVA challenge and a signiﬁcant increase was detected after
the second OVA challenge (d.22) (Figure 3(a)). As expected,
thenumberofeﬀector(CD4+CD25+Foxp3−)T(T eﬀ)cellsin
allergic mice also increased after the ﬁrst (d.17) and second
OVA challenge (Figure 3(b)). Similar results were found in
the lungs of allergic group where the frequency and number
of both Treg and Teﬀ cells increased after ﬁrst and second
OVA challenge (Figures 3(c), 3(d),a n d3(e)). In allergic
group at day 22, the number and frequency of Teﬀ cells in
the BAL and lung tissue were more than 4-fold higher than
Treg cells (Figures 3(a), 3(b),a n d3(c)). These results clearly
document that Treg cells are recruited at sites of allergen
challenge only in mice experiencing allergic inﬂammation.
3.4. Lung Inﬁltrating Regulatory T Cells Expresses an Eﬀec-
tor/Memory Phenotype. Because Treg cells were recruited
to the airways of allergic mice, we reasoned that these
cells might have acquired a migratory phenotype similar to
Th2 cells that inﬁltrate lung tissue [31, 32]. Therefore, we
analyzed several T-cell surface molecules associated with T-
cell migration and/or activation. As shown in Figure 4(a)
by mean ﬂuorescence intensity (MFI) into each FACS-
histogram, the BAL CD4+Foxp3+ Treg cells from allergic
mice upregulated the chemokine receptor CCR4 but not
CCR7, downregulated L-selectin (CD62L) and upregulated
ICAM-1 (CD54) when compared with CD4+Foxp3+ Treg
cells from lung draining lymph nodes (dLN) (Figure 4(a)
upper histograms). To further characterize the phenotype of
these Treg cells, we determined the expression of activation6 Clinical and Developmental Immunology
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Figure 3: Regulatory T cells accumulate in the airways of allergic but not tolerant mice. Time course of (a) CD4+CD25+Foxp3+ (Treg) and
(b) CD4+CD25+Foxp3− (Teﬀ) cells number in the BAL of allergic and tolerant mice. (c) Frequency and (d) number of CD4+CD25+ lung
cells expressing or not Foxp3. Pooled cells from three mice recovered from BAL and lung were stained for CD4, CD25, and Foxp3 and gated
in CD4-positive cells. Values in (a) and (b) represent the means ± SEM for groups of three mice and are representative of two experiments.
The data in (c) show a representative experiment of two. Signiﬁcant diﬀerences ∗∗P<0.01, ∗∗∗P<0.001 are related to tolerant group.Clinical and Developmental Immunology 7
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Figure 4: Airway regulatory T cells from allergic mice express a memory/eﬀector phenotype. (a) FACS-Histograms of CD4+Foxp3+ cells
from allergic mice expressing CCR4, CCR7, CD62L, CD54, CD44, CTLA-4, GITR, CD25 in BAL (red line), or mediastinal draining lymph
nodes (dLN) (blue line). The numbers into each histogram represent the mean ﬂuorescence intensity (MFI). Kinetic of lung CD4+CD69+
cells frequency expressing or not Foxp3. (c) Percentage of BAL CD4+CD69+ cells expressing or not Foxp3. Pooled cells from four mice
recovered from lung or BAL were stained for CD4, CD69, and Foxp3 and gated in CD4-positive cells. The results are representative of two
experiments with four mice per group.
markers. We found that BAL CD4+Foxp3+ Treg cells from
allergic mice also upregulated CD44, CTLA-4, GITR, and
CD25 (Figure 4(a) lower histograms). Moreover, in lung
tissue the frequency of CD4+Foxp3+ Treg cells expressing
CD69 molecule increased substantially after OVA challenge
in allergic mice compared to tolerant mice (Figure 4(b)). As
expected, the frequency of Foxp3-negative CD69+ Th e l p e r
(Teﬀ) cells was drastically enhanced in allergic but not in
tolerant group after OVA challenges (Figure 4(b)). Similar
results were obtained with T cells present in BAL at day 22
(Figure 4(c)). Notably, the frequency of CD69+ Treg cells in
the lung and BAL of allergic mice was higher than CD69−
Treg cells, whereas in tolerant mice we found an inverse
relation (Figure 4(c)). Taken together, our ﬁndings clearly
indicate that inﬁltrating Foxp3+ Treg cells from allergic mice
acquire an eﬀector/memory phenotype distinguishing them
from Treg cells present in lung-draining lymph nodes and
from those present in the airways of tolerant mice.
3.5. Regulatory T Cells Recruited to the Airways of Allergic
Mice Are Not the Principal Producers of Suppressive Cytokines.
Interleukin-10 (IL-10) and transforming growth factor-β
(TGF-β) have been implicated in suppression of inﬂamma-
tionbyTregcells[33–36].Therefore,weinvestigatedwhether
airway inﬁltrating Treg cells from allergic mice produce these
cytokines. We ﬁrst determined the levels of IL-10 and TGF-
β in BAL ﬂuid. We found that high levels of IL-10, total,
and bioactive TGF-β were signiﬁcantly increased in the BAL
of allergic mice compared to control or tolerant groups
(Figures 5(a), 5(b),a n d5(c)). To ascertain whether Treg8 Clinical and Developmental Immunology
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Figure 5: Regulatory T cells are not the major producer of suppressive cytokines in the BAL. Quantiﬁcation by ELISA of BAL (a) IL-10, (b)
total, and (c) bioactive TGF-β of BALB/c control, allergic and tolerant mice upon 24h of the last OVA challenge. (d) IL-10, LAP, and IL-5
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two experiments. Signiﬁcant diﬀerences ∗P<0.05, ∗∗∗P<0.05 are shown.
cells of allergic mice produce these suppressive cytokines,
we stained CD4+Foxp3+ T cells for intracellular IL-10 or
for latent-associated peptide (LAP) to indirectly detect TGF-
β producing cells. TGF-β complexes with latency-associated
peptide (LAP), and LAP expression correlates with TGF-
β production in many cell types [37–39]. We found that
only CD4+Foxp3− cells stained positively for IL-10. The
expression of LAP was found in both Foxp3− and Foxp3+
cells, however, the majority (25%) of CD4+ cells in the
BALexpressingLAPwereFoxp3− (Figure 5(d)).Asexpected,
Foxp3+ T cells did not produce IL-5 (Figure 5(d)). These
results indicate that high levels of suppressive cytokines at
site of allergen challenge are associated with lung allergic
inﬂammation and that CD4+Foxp3+ Treg cells in the airways
of allergic mice do not produce IL-10 and are not the major
population of TGF-β producing cells.
3.6. Lung Treg Cells of Allergic Mice Exhibit Strong Antipro-
liferative Activity but Are Unable to Suppress Type-2 Cytokine
Production. Finally, to address the role of Treg cells present
in the lung of allergic mice, we performed a standard in
vitrosuppression assay [40, 41], as previously described [24].
First, we tested the proliferative activity of CD4+CD25−
(memory/eﬀector T cells) cells from lung upon anti-CD3
stimulation in the presence or absence of CD4+CD25+
cells. As shown in Figure 6(a),l u n gC D 4 +CD25− cells
exhibited high proliferative response upon anti-CD3 anti-
body stimulation whereas lung CD4+CD25+ cells did not
proliferate. Coculture of CD4+CD25+ with CD4+CD25−
cells showed that CD25+ cells almost completely suppressed
CD25− cell proliferation at ratio 1:1, partially at 0.3:1
but not at 0.1:1 (Figure 6(a)). Next, we evaluated the
production of Th2-cytokine by lung CD4+CD25− cells
in the presence or absence of CD4+CD25+ cells. Albeit
CD4+CD25+ cells eﬃciently suppressed T-cell proliferation,
they were unable to inhibit IL-4 and IL-5 production upon
anti-CD3 stimulation (Figures 6(b) and 6(c)). Similar data
were found when these cells were stimulated speciﬁcally
with OVA (data not shown). The lack of inhibition of IL-
4 and IL-5 secretion by CD4+CD25+ c e l l sm i g h tb ed u et oClinical and Developmental Immunology 9
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Figure 6: Lung CD4+CD25+ T cells from allergic mice suppress T-cell proliferation but not Th2 cytokine production. (a) Proliferation of
MACS-puriﬁed lung CD4+CD25− or CD4+CD25+ cells from BALB/c allergic mice alone or cocultured at diﬀerent CD25−/CD25+ ratios
determined by 3H-thymidine (3H-TdR) incorporation after anti-CD3 stimulation. ELISA assays for (b) IL-4 and (c) IL-5 in the culture
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Signiﬁcant diﬀerences ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 are shown.
the fact that this cell population also contains eﬀector T cells.
Indeed, CD4+CD25+ cells produced signiﬁcant amounts
of type-2 cytokines (Figures 6(b) and 6(c)). In order to
circumvent this problem and address more directly whether
Treg cells aﬀect type-2 cytokine production, we performed
experiments in Foxp3gfp.KI mice that harbor ﬂuorescent
Treg cells [29]. Therefore, we induced airway allergic disease
in Foxp3gfp.K Im i c ea n ds o r t e dC D 4 + T cells expressing
Foxp3-GFP+ Treg cells and CD4+GFP− Tc e l l s( F o x p 3 −)
present in the lungs. We found that only Foxp3− Tc e l l s
produced signiﬁcant amounts of type 2 cytokines upon
anti-CD3 stimulation (Figures 7(a) and 7(b)). Notably, a
highly puriﬁed (>98%) lung population of Foxp3-GFP+ Treg
cells could not suppress eﬃciently Th2 cytokine production
by CD4+Foxp3-GFP− T cells upon anti-CD3 stimulation
(Figures 7(a) and 7(b)). Finally, through using puriﬁed
lung Foxp3-GFP+ Treg cells, we conﬁrmed the suppression
assay obtained with CD4+CD25+ T-cell by showing that
they eﬃciently suppressed T eﬀector (CD4+GFP−)c e l l s
proliferation at ratio 1:1 and 0.3:1 but not at 0.1:1 as
evidenced by Dye eFluor-670 staining (Figure 7(c)). We
conclude that lung Treg cells with regulatory phenotype
present in the airways of allergic mice exhibit a strong
antiproliferativeactivitybutareunabletoeﬃcientlysuppress
type-2 cytokine production.
4. Discussion
A critical issue in immune regulation is where Treg cells
exert their suppressive function. Their presence on lymphoid
tissueappearstoberequiredforeﬃcientsuppressionofnaive
T-cell activation. Conversely, some data indicate that Treg
cells are recruited to eﬀector site in order to suppress the
action of inﬂammatory T cells [25, 42, 43]. Previous reports
showed a relationship between suppression of asthma-like
responses by mucosal tolerance and the emergence of Treg
c e l l si nl y m p h o i do r g a n s[ 17, 21, 24]. We have previously
shown in T/B receptors transgenic mice (T-Bmc) devoid of
natural regulatory T cells that soon after mucosal antigen
exposure, Foxp3-expressing Treg cells are generated in dLN
a n di ns p l e e n[ 24]. This early induction of Treg cells by prior
oral antigen exposure appears to inhibit the development
of polarized Th2 inﬂammatory cells in a TGF-β-dependent
manner [24]. Indeed, using the T-Bmc model, we found that
T r e gc e l l sa r ea b l et os u p p r e s se a r l yT - c e l la c t i v a t i o n ,4 8 h
after immunization with the cognate antigen [24]. However,
after establishment of tolerance they became dispensable for
its maintenance in situ. In the present study, we used a
well-established model of mucosal tolerance to allergic lung
inﬂammation [8, 12, 24, 44] to monitor the appearance
of Treg cells in the airways after OVA challenge in mice
with polyclonal repertoire. We found that only in OVA-
fed mice, the frequency of spleen Treg cells increased at
day 3 after OVA sensitization, a result resembles the T-
Bmc model. However, here we were particularly interested in
determining whether Treg cells migrate to airways of allergic
or tolerant mice after administration of OVA. We found that
allergic but not tolerant mice showed a striking increase in
the number of Treg cells in the BAL compared to tolerant
m i c e .A l s o ,h i g hl e v e l so fI L - 1 0a n dT G F - β were detected in
the airways of allergic mice. Notably, we found that among
CD4+ T cells recruited to allergic inﬂammation only Foxp3-
negative, but not Foxp3-positive T cells stained positively
for IL-10. Moreover, the majority of LAP+ c e l l sw e r eF o x p 3 -
negative T cells. Our results are line with data obtained with
T-cell inﬁltrates in Shcistosoma mansoni egg-induced Th2-
mediated inﬂammation [45]. In concert with our ﬁndings,
migration of Treg cells was also reported in a model of
parasite egg antigens-induced inﬂammation [46], or other
pathological conditions, such as arthritis, type 1 diabetes,
sarcoidosis and transplants [25, 43, 47–52]. Therefore, it
is plausible that the allergic inﬂammatory milieu triggers
the migration of Treg cells into the airways. Accordingly, it
has been shown that recruitment of Foxp3-expressing Treg
cells to the site of allergic inﬂammation is dependent on
chemokine receptors such as CCR4 [52] and CCR8 [53],
where their ligands CCL17, CCL22, and CCL1 are high
expressed during allergic lung inﬂammation [54, 55]. Our
data demonstrated that the majority of Foxp3-expressing
Treg cells present in the airways upregulated CCR4, CD4410 Clinical and Developmental Immunology
Dye
(a)
(b)
T
e
f
f
:
T
r
e
g
c
e
l
l
s
(c)
61.5
56.5
44
26.8
Foxp3− Foxp3+
0
20
40
60
80 ∗∗
Foxp3−/Foxp3+
I
L
-
4
(
p
g
/
m
L
)
Foxp3− Foxp3+
0
20
40
60
80
100
120 ∗∗∗
Foxp3−/Foxp3+
I
L
-
5
(
p
g
/
m
L
)
1 : 0.1 1 : 0.3 1 : 1
1:0 . 1 1:0 . 3 1:1
1:0
1 : 0.1
1:0 . 3
1:1
Figure 7: Lung Foxp3+ Treg cells from allergic mice suppress T-cell proliferation but not type 2 cytokine production. (a) IL-4 and (b) IL-5
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diﬀerences ∗∗P<0.01, ∗∗∗P<0.001 are shown.
and CD54 and drastically downregulated CD62L, a pheno-
type that resembles eﬀector/memory T cells. Noteworthy,
this phenotype could distinguish Treg cells present in the
airways from those present in the lung-draining lymph
nodes (dLN). In addition, we showed that Treg cells that
accumulated in the airways of allergic mice also acquired
activated phenotype, as revealed by increased expression of
CTLA-4,GITR,andCD25contrastingwithTregcellspresent
in the dLN. Moreover, CD69, a marker of cell activation, was
highly expressed in Treg cells present in the lung and BAL of
allergic mice but not in tolerant group. These data suggest
a functionally important activation step that accompanies
Treg cell migration. The loss of CD62L and the increased of
CD54 expression by Treg cells could also contribute to their
migration to the lung [32]. A picture that emerges from our
ﬁndings is that Treg cells get activated and are recruited to
sites of allergic inﬂammation probably because at these sites
CCR4-speciﬁc ligands are expressed at high levels [28, 56].
It was recently reported that the loss of CCR4 severely
inhibited the accumulation of CD4+CD25+ T cells in the
lung and skin [57]. CCR4 knockout mice also fail to develop
allograft tolerance after administration of anti-CD154 with
donor spleen cells, which is associated with a decreased of
Foxp3+ T cells in the graft [43]. Previous data indicated
a division of labor between naive and activated Treg cells
[58]. For instance, naive-like Treg cells use the chemokine
receptor CCR7 for recirculation through lymph nodes where
they control the priming phase of an immune response
whereas CCR7 is dispensable in eﬀector/memory-like Treg
cells for their accumulation in inﬂamed sites and in fact
CCR7-deﬁciency enhance Treg cells-mediated suppression
of inﬂammation [58]. In our model, the role of CCR7
could not be established because activated lung Treg cells
expressed similar levels of CCR7 when compared to naive
dLN Treg cells [25]. Using an islet allograft model it was
demonstrated that Treg cells ﬁrst migrate from blood to the
allograftwherethey become activated, and then theymigrate
to the dLN in a CCR7 fashion. This movement was essential
for optimal suppression allograft rejection [25]. A similar
situation was found by Graca et al. that found regulatoryClinical and Developmental Immunology 11
T cells in skin allografts suggesting that T-cell suppression of
graft rejection is an active process that involves the presence
of regulatory T cells at the site of the tolerated transplant
[59]. This scenario does not appear to operate in our model
because we did not ﬁnd Treg cells in dLN with an activated
phenotype.
We ﬁrst studied the suppressive activity of airway
CD4+CD25+ Tcells,putativeTregcells,inordertodetermine
their role in lung inﬂammation. We clearly showed that
CD4+CD25+ T cells containing activated Foxp3+ Treg cells
eﬃciently suppressed the proliferation of lung CD4+CD25−
memory/eﬀector T cells. Strikingly, these CD4+CD25+ T
cells did not suppress the secretion of IL-4 and IL-5 by
anti-CD3 or OVA-activated CD4+CD25− T cells. Because
CD4+CD25+ T cells contain also eﬀector Foxp3-negative
T cells, it is likely that these cells were the source of the
type 2 cytokines detected in the cultures. To circumvent this
we puriﬁed lung ﬂuorescent Foxp3 Treg cells from allergic
Foxp3gfp.KI mice and tested their suppressive activity on
type 2 cytokine production by Foxp3-negative CD4+ T cells.
In this situation, Foxp3-positive Treg cells did not secrete
type 2 cytokines and did not suppress signiﬁcantly type 2
cytokine production by Foxp3-negative CD4+ T cells but
did suppress CD4+ T-cell proliferation. These results could
explainwhy,despitethelargeinﬁltrationofTregcells,allergic
mice still show Th2-associated pathological responses. Our
results are in line with previous ﬁnding showing that in
allergic patients, CD4+CD25+ T cells did not suppress
the release of Th2 cytokines [6]. The ineﬃciency of Treg
cell in suppressing inﬂammatory cytokines in established
pathological conditions was also reported in sarcoid gran-
ulomas, in which Treg cells suppressed T-cell proliferation
but were unable to inhibit TNF-α secretion [51]. Notably,
in a model of autoimmune encephalomyelitis, Treg cells also
expand after exposure to myelin antigens and inﬁltrate the
central nervous system, but these inﬁltrating Treg cells were
unable to suppress proliferation and inﬂammatory cytokine
production of eﬀector T cells from target tissue [60]. Based
on our results and previous reports, it appears that the
inﬂammatory milieu impairs Treg-cell functions.
In summary, we showed that oral tolerance was not asso-
ciated with an increased number of Treg cells or suppressive
cytokines in the airways. Conversely, allergic inﬂammation
triggers the inﬁltration of Treg cells into the airways that
eﬃciently suppress T-cell proliferation but not Th2 cytokine
production. Our ﬁndings suggest that allergic inﬂammation
renders the suppressive activity of Treg cells less stringent
that, in turn, allows the manifestations allergic reactions
mediated by type 2 cytokines.
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